Clinical Evaluation of the AP203 Plant Extract Mixture in Adult Patients With Increased Incidence of Viral and/or Bacterial Upper Respiratory Tract Infections

Inclusion Criteria: * Women and men, 18-70 years old * Healthy patients at the time of enrollment to the study (without active upper respiratory tract infection) * Presence of 2 or more episodes of upper respiratory tract infections or \>=2 episodes of cold during the year * Patients with chronic upper respiratory tract diseases including bronchial asthma * Signed informed consent * Women: contraception or postmenopausal age Exclusion Criteria: * Intake of supplements containing plant extracts, polyphenols or anthocyanins for the 3 months prior to the study initiation * Acute inflammation * Oral immunosuppressive drugs * Steroid, anti-allergic drugs in exacerbations of chronic disease at least 2 months from the start of study participation * Antibiotic therapy 1 month prior to study initiation * Participation in another clinical trial; * Oncological disease, autoimmune disease, severe liver dysfunction, tuberculosis, leukaemia, multiple sclerosis, AIDS, rheumatoid arthritis, organ transplantation; * Hypersensitivity/allergy to any of the ingredients of the product, allergy to plants of the Asteraceae family (e.g. chamomile, calendula); * Women who are pregnant or planning to become pregnant during the study period;